A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)

SIMPLE SUMMARY: Ketamine has demonstrated rapid antidepressant effects, but has been minimally studied in cancer populations. We conducted an open-label trial evaluating ketamine for depression in patients with advanced cancer. Participants received three flexible doses of intranasal (IN) ketamine (...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblat, Joshua D., deVries, Froukje E., Doyle, Zoe, McIntyre, Roger S., Rodin, Gary, Zimmermann, Camilla, Mak, Ernie, Hannon, Breffni, Schulz-Quach, Christian, Kindy, Aida Al, Patel, Zeal, Li, Madeline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857323/
https://www.ncbi.nlm.nih.gov/pubmed/36672348
http://dx.doi.org/10.3390/cancers15020400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857323/
https://www.ncbi.nlm.nih.gov/pubmed/36672348
http://dx.doi.org/10.3390/cancers15020400

Ejemplares similares